Huntington disease in Asia

Chinese Medical Journal

Volumn 128, Issue 13, 2015, Pages 1815-1819

  Xu, Miao ^a   Wu, Zhi Ying ^a,b  

^a FUDAN UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

China; Genotype; Huntington disease; Phenotype

Indexed keywords

TETRABENAZINE;

ASIA; ATAXIA; CAG REPEAT; CAUCASIAN; CLINICAL FEATURE; DYSTONIA; GENE THERAPY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; PARKINSONISM; PHENOTYPE; REVIEW; SPASTICITY; TIC; GENETICS; HUNTINGTON DISEASE;

ASIA; GENOTYPE; HAPLOTYPES; HUMANS; HUNTINGTON DISEASE; PHENOTYPE;

EID: 84933556800     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.4103/0366-6999.159359     Document Type: Review

References (50)

1. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Mov Disord 2012;27:1083-91.
2. Squitieri F, Andrew SE, Goldberg YP, Kremer B, Spence N, Zeisler J, et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 1994;3:2103-14.
3. Zheng Z, Burgunder JM, Shang H, Guo X. Huntington’s like conditions in China, A review of published Chinese cases. PLoS Curr 2012;4:RRN1302.
4. Shin CW, Choi YJ, Kim M, Jeon BS. Preliminary analysis of Huntington’s disease in South Korea. J Huntingtons Dis 2013;2:83-7.
5. Morovvati S, Nakagawa M, Osame M, Karami A. Analysis of CCG repeats in Huntingtin gene among HD patients and normal populations in Japan. Arch Med Res 2008;39:131-3.
6. Becker N, Munhoz RP, Raskin S, Werneck LC, Teive HA. Non-choreic movement disorders as initial manifestations of Huntington’s disease. Arq Neuropsiquiatr 2007;65:402-5.
7. Ashizawa T, Wong LJ, Richards CS, Caskey CT, Jankovic J. CAG repeat size and clinical presentation in Huntington’s disease. Neurology 1994;44:1137-43.
8. Dong Y, Sun YM, Liu ZJ, Ni W, Shi SS, Wu ZY. Chinese patients with Huntington’s disease initially presenting with spinocerebellar ataxia. Clin Genet 2013;83:380-3.
9. Kageyama Y, Yamamoto S, Ueno M, Ichikawa K. A case of adult-onset Huntington disease presenting with spasticity and cerebellar ataxia, mimicking spinocerebellar degeneration. Rinsho Shinkeigaku 2003;43:16-9.
10. Liu ZJ, Sun YM, Ni W, Dong Y, Shi SS, Wu ZY. Clinical features of Chinese patients with Huntington’s disease carrying CAG repeats beyond 60 within HTT gene. Clin Genet 2014;85:189-93.
11. Chuo YP, Hou PH, Chan CH, Lin CC, Liao YC. Juvenile Huntington’s disease presenting as difficult-to-treat seizure and the first episode of psychosis. Gen Hosp Psychiatry 2012;34:436.e9-11.
12. Gonzalez-Alegre P, Afifi AK. Clinical characteristics of childhood-onset (juvenile) Huntington disease: Report of 12 patients and review of the literature. J Child Neurol 2006;21:223-9.
13. Nance MA. Genetic testing of children at risk for Huntington’s disease. US Huntington Disease Genetic Testing Group. Neurology 1997;49:1048-53.
14. Hao Y, Chen YY, Gu WH, Wang GX, Ma HZ, Li LL, et al. Clinical and genetic study of a juvenile-onset Huntington disease. Chin J Contemp Neurol Neurosurg 2012;12:288-93.
15. Dürr A, Dodé C, Hahn V, Pêcheux C, Pillon B, Feingold J, et al. Diagnosis of "sporadic" Huntington’s disease. J Neurol Sci 1995;129:51-5.
16. Davis MB, Bateman D, Quinn NP, Marsden CD, Harding AE. Mutation analysis in patients with possible but apparently sporadic Huntington’s disease. Lancet 1994;344:714-7.
17. Wang YX, Zhang BS. Clinical phenotype and genetic analysis of sporadic Huntington’s disease clinical phenotype and genetic analysis (in Chinese). Tianjin Med J 2010;38:1006-7.
18. Alonso ME, Yescas P, Rasmussen A, Ochoa A, Macías R, Ruiz I, et al. Homozygosity in Huntington’s disease: New ethical dilemma caused by molecular diagnosis. Clin Genet 2002;61:437-42.
19. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330:1401-6.
20. Shi SS, Lin Y, Zhao GX, Gan SR, Wu ZY. A Chinese pedigree with an individual homozygous for CAG repeats of Huntington’s disease. Psychiatr Genet 2012;22:53-4.
21. Wang CK, Wu YR, Hwu WL, Chen CM, Ro LS, Chen ST, et al. DNA haplotype analysis of CAG repeat in Taiwanese Huntington’s disease patients. Eur Neurol 2004;52:96-100.
22. Soong BW, Wang JT. A study on Huntington’s disease associated trinucleotide repeat within the Chinese population. Proc Natl Sci Counc Repub China B 1995;19:137-42.
23. Pramanik S, Basu P, Gangopadhaya PK, Sinha KK, Jha DK, Sinha S, et al. Analysis of CAG and CCG repeats in Huntingtin gene among HD patients and normal populations of India. Eur J Hum Genet 2000;8:678-82.
24. Pulkes T, Papsing C, Wattanapokayakit S, Mahasirimongkol S. CAG-expansion haplotype analysis in a population with a low prevalence of Huntington’s disease. J Clin Neurol 2014;10:32-6.
25. Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M, et al. Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet 1993;4:387-92.
26. Langbehn DR, Hayden MR, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 2010;153B: 397-408.
27. Aziz NA, Jurgens CK, Landwehrmeyer GB, EHDN Registry Study Group, van Roon-Mom WM, van Ommen GJ, et al. Normal and mutant HTT interact to affect clinical severity and progression in Huntington disease. Neurology 2009;73:1280-5.
28. Jiang H, Sun YM, Hao Y, Yan YP, Chen K, Xin SH, et al. Huntingtin gene CAG repeat numbers in Chinese patients with Huntington’s disease and controls. Eur J Neurol 2014;21:637-42.
29. Ravina B, Romer M, Constantinescu R, Biglan K, Brocht A, Kieburtz K, et al. The relationship between CAG repeat length and clinical progression in Huntington’s disease. Mov Disord 2008;23:1223-7.
30. Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009;84:351-66.
31. Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur J Hum Genet 2011;19:561-6.
32. Pêcheux C, Mouret JF, Dürr A, Agid Y, Feingold J, Brice A, et al. Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes. J Med Genet 1995;32:399-400.
33. Ma M, Yang Y, Shang H, Su D, Zhang H, Ma Y, et al. Evidence for a predisposing background for CAG expansion leading to HTT mutation in a Chinese population. J Neurol Sci 2010;298:57-60.
34. Zhang BR, Tian J, Yan YP, Yin XZ, Zhao GH, Wu ZY, et al. CCG polymorphisms in the huntingtin gene have no effect on the pathogenesis of patients with Huntington’s disease in mainland Chinese families. J Neurol Sci 2012;312:92-6.
35. Masuda N, Goto J, Murayama N, Watanabe M, Kondo I, Kanazawa I. Analysis of triplet repeats in the huntingtin gene in Japanese families affected with Huntington’s disease. J Med Genet 1995;32:701-5.
36. Vonsattel JP, Keller C, Cortes Ramirez EP. Huntington’s disease-neuropathology. Handb Clin Neurol 2011;100:83-100.
37. Wu AG, Wong VK, Xu SW, Chan WK, Ng CI, Liu L, et al. Onjisaponin B derived from radix polygalae enhances autophagy and accelerates the degradation of mutant a-synuclein and huntingtin in PC-12 cells. Int J Mol Sci 2013;14:22618-41.
38. Xiao G, Fan Q, Wang X, Zhou B. Huntington disease arises from a combinatory toxicity of polyglutamine and copper binding. Proc Natl Acad Sci U S A 2013;110:14995-5000.
39. Parkinson’s disease and movement disorder group in Neurologic Branch of Chinese Medical Association. Guideline for diagnosis and treatment of Huntington’s disease. Chin J Neurol 2011;44:638-41.
40. Agostinho LA, Dos Santos SR, Alvarenga RM, Paiva CL. A systematic review of the intergenerational aspects and the diverse genetic profiles of Huntington’s disease. Genet Mol Res 2013;12:1974-81.
41. Biglan KM, Ross CA, Langbehn DR, Aylward EH, Stout JC, Queller S, et al. Motor abnormalities in premanifest persons with Huntington’s disease: The PREDICT-HD study. Mov Disord 2009;24:1763-72.
42. Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010;82:201-7.
43. Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: Analysis of 24 month observational data. Lancet Neurol 2012;11:42-53.
44. Aylward EH, Nopoulos PC, Ross CA, Langbehn DR, Pierson RK, Mills JA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2011;82:405-10.
45. Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC, et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 2011;25:1-14.
46. Kincses ZT, Szabó N, Tóth E, Zádori D, Faragó P, Németh D, et al. Diffusion MRI measured white matter microstructure as a biomarker of neurodegeneration in preclinical Huntington’s disease. Ideggyogy Sz 2013;66:399-405.
47. Georgiou-Karistianis N, Scahill R, Tabrizi SJ, Squitieri F, Aylward E. Structural MRI in Huntington’s disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev 2013;37:480-90.
48. Johnson CD, Davidson BL. Huntington’s disease: Progress toward effective disease-modifying treatments and a cure. Hum Mol Genet 2010;19:R98-102.
49. Nance MA. Therapy in Huntington’s disease: Where are we? Curr Neurol Neurosci Rep 2012;12:359-66.
50. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev 2009;(3):CD006456.